Saturday - April 19, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

Marpai to Host Call on March 30, 2023 to Discuss Fourth Quarter & Full Year 2022 Financial Results

March 20, 2023 | Last Trade: US$1.05 0.10 10.40

NEW YORK / Mar 20, 2023 / Business Wire / Marpai, Inc. ("Marpai" or the “Company”) (Nasdaq: MRAI), a deep learning technology company transforming third-party administration (TPA) in the self-funded health insurance market, will host a conference call and webcast on Thursday, March 30 at 8:30 a.m. ET to answer questions about the Company's operational and financial highlights for its fourth quarter and the full year 2022. The Company will report its fourth quarter and full year results after the close of trading on Wednesday, March 29, 2023.

Event: Marpai Fourth Quarter and full year 2022 Financial Results Conference Call

Date: Thursday, March 30, 2023

Time: 8:30 a.m. Eastern Time

Live Call: US: 1-866-652-5200 / CAN: 1-855-669-9657 / INT TOLL: 1 412-317-6060

Webcast: https://app.webinar.net/07JEr5B2x8G

About Marpai, Inc.

Marpai, Inc. (Nasdaq: MRAI) is a technology company bringing AI-powered health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA (Third Party Administrator) sector serving self-funded employer health plans representing over $1 trillion in annual claims, Marpai maximizes the value of the health plan as measured in health outcomes. Marpai takes a member-centric approach that uses AI and big data to connect members to health solutions predicted to have a high probability of positive outcomes, and aims to bring value-based care to the self-insured market. With effective early intervention, disease management, claims processing and proactive member outreach, Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com.

Forward-looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “can,” “could”, “will”, “potential”, “should,” “goal” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai’s current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai’s current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events, or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai’s filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov.

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page